Affimed NV (NASDAQ:AFMD) has been downgraded to Sell in a report by Zacks Investment Research today.
- Updated: October 12, 2016
Only yesterday Affimed NV (NASDAQ:AFMD) traded 0.00% even at $2.41. Affimed NV’s 50-day moving average is $2.71 and its 200-day moving average is $3.20. The last stock close price is down -24.75% relative to the two hundred day average, compared with the S&P 500 Index which has decreased -0.01% over the same period. Trading volume was up over the average, with 121,365 shares of AFMD changing hands over the typical 111,185
Zacks Investment Research has downgraded Affimed NV (NASDAQ:AFMD) to Sell in a statement released on 10/12/2016.
Recent Performance Chart
With a total market value of $0, Affimed NV has with a one year low of $2.25 and a 52 week high of $8.42 .
In addition to Zacks Investment Research reporting its target price, a total of 5 firms have released a report on Affimed NV. The 12-month price target is $10.52 with 3 brokerages rating the stock a strong buy, 2 firms rating the stock a buy, one analyst rating the company a hold, zero equity analysts rating the company a underperform, and lastly zero analysts rating the company a sell.
More About Affimed NV (NASDAQ:AFMD)
Affimed N.V. is a clinical-stage biopharmaceutical company focused on discovering and developing cancer immunotherapies. The Company's product candidates are developed in the field of immuno-oncology, which represents an approach to cancer research that seeks to harness the body's own immune system to fight tumor cells. Its pipeline includes FM13, AFM11, AFM21, AFM22, AFM24, TandAb and Trispecific Abs. It has started recruitment for Phase IIa clinical trial of AFM13 in patients with Hodgkin Lymphoma. It has initiated a Phase I clinical trial of AFM11 in patients with non-Hodgkin Lymphoma. AFM21 is in preclinical development. AFM22, which is an Epidermal Growth Factor Receptor variant III (EGFRvIII)/CD16A NK-cell TandAb is in preclinical development. AFM24 is an additional CD16A NK-cell TandAb targeting a validated solid tumor target, EGFR-wild type. It is developing Trispecific Abs for treating multiple myeloma, and CD33/CD3-specific T-cell TandAb to treat acute myeloid leukemia.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with MarketBeat.com's FREE daily email newsletter.